POP Biotechnologies' next-gen vaccine technology to enter COVID-19 phase III clinical trials

Digital Journal, Market Screener, and other websites report that a COVID-19 vaccine candidate, EuCorVac-19, developed by UB spinoff POP Biotechnologies and South Korean pharmaceutical company EuBiologics has been approved for a phase 3 clinical study in South Korea.

"The goal of the large scale clinical testing of this next-generation technology is to add a new vaccine tool to the arsenal for combating COVID-19," said POP Bio co-founder Jonathan Lovell, SUNY Empire Innovation Associate Professor of Biomedical Engineering.

Read the story in Market Screener and Digital Journal here.